Add to a list

Inactive Instrument

Pear Therapeutics, Inc. Share Price

PEAR

US7047231052

Biotechnology & Medical Research

OTC Markets Traded

Latest news: Pear Therapeutics, Inc.

23/05/24	Pear Therapeutics, Inc. Went Out of Business	CI
08/05/24	Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc.	CI
22/03/24	Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc.	CI
04/03/24	Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc.	CI
12/02/24	Third Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	CI
13/12/23	Second Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	CI
04/08/23	First Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	CI
20/07/23	First Motion for Exclusivity Period Extension Filed by Pear Therapeutics, Inc.	CI
23/05/23	Motion for Asset Sale Approved for Pear Therapeutics, Inc.	CI
23/05/23	Motion for Asset Sale Approved for Pear Therapeutics, Inc.	CI
21/05/23	Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	CI
20/05/23	Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	CI
19/05/23	Notice of Auction Resluts Filed by Pear Therapeutics, Inc.	CI

More news

Analysts' recommendations: Pear Therapeutics, Inc.

20/03/23	Credit Suisse Downgrades Pear Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $7	MT
20/03/23	TD Cowen Downgrades Pear Therapeutics to Market Perform From Outperform	MT
20/03/23	Chardan Downgrades Pear Therapeutics to Neutral From Buy, Citing Cash Constraints, Withdraws Price Target	MT
16/11/22	Citigroup Adjusts Price Target on Pear Therapeutics to $5 From $7, Maintains Buy Rating	MT
15/11/22	Credit Suisse Lowers Pear Therapeutics' PT to $7 From $9, Updates Model After Q3 Actuals, Management Guidance; Keeps Outperform Rating	MT

More recommendations

Press Releases: Pear Therapeutics, Inc.

10/04/23	PEAR THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
10/04/23	PEAR THERAPEUTICS FILES FOR CHAPTER 11 AND WILL SEEK TO SELL ASSETS THROUGH SALES PROCESS	AQ
07/04/23	PEAR THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
07/04/23	Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process	BU
31/03/23	PEAR THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ

More press releases

News in other languages: Pear Therapeutics, Inc.

16/02/22

Pear Therapeutics anuncia que ya están disponibles las versiones en español de reSET® y reSET-O®

More news

Managers and Directors: Pear Therapeutics, Inc.

Manager	Title	Age	Since
Maria Sullivan CTO	Chief Tech/Sci/R&D Officer	-	-
Ilya Gluhovsky CTO	Chief Tech/Sci/R&D Officer	-	-
Yuri Maricich CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Shiva Rajaraman BRD	Director/Board Member	52	13/06/2022

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PEAR THERAPEUTICS, INC.	-.--%	-.--%	-	-	142
WUXI APPTEC CO., LTD.	+2.41%	-6.33%	+43.43%	+71.02%	63.29B
ARGENX SE	-0.15%	+3.11%	+10.29%	+72.56%	54.89B
LONZA GROUP AG	+0.57%	+4.64%	+12.82%	+89.79%	53.28B
IQVIA HOLDINGS INC.	+0.37%	+3.07%	+28.23%	+51.53%	45.81B
BEONE MEDICINES AG	-1.21%	+0.95%	+20.44%	+128.58%	43.46B
REVOLUTION MEDICINES, INC.	-0.37%	-1.20%	+252.94%	+568.54%	40.23B
CELLTRION, INC.	+0.05%	+6.75%	+14.48%	+56.75%	33.45B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-5.84%	+27.86%	-0.65%	23.7B
GENMAB A/S	-0.38%	+4.55%	+37.71%	+28.10%	23.76B
Average	+0.25%	+0.33%	+49.80%	+118.47%	42.43B
Weighted average by Cap.	+0.38%	+0.55%	+48.17%	+122.11%

See all sector performances

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâ€™s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Employees

200

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
PEAR Stock

The best tools reserved for subscribers to boost the performance of your investments!

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/04/23	5AM Venture Management LLC	Sell	Company	16,544,113	11.8148%
15/02/23	Christopher Guiffre	Free	Chief Executive Officer	2,285,714	1.6323%
15/02/23	Yuri Maricich	Free	Chief Technology Officer	1,333,333	0.9522%

Pear Therapeutics, Inc. Share Price

Stocks

PEAR

US7047231052

Biotechnology & Medical Research

Latest news: Pear Therapeutics, Inc.

Analysts' recommendations: Pear Therapeutics, Inc.

Press Releases: Pear Therapeutics, Inc.

News in other languages: Pear Therapeutics, Inc.

Managers and Directors: Pear Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile